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Abstract.  The role of basic fibroblast growth factor- 
(bFGF) induced proteinases in basement membrane 
(BM) invasion by bovine capillary endothelial (BCE) 
cells was studied using a quantitative  in vitro assay 
previously described (Mignatti et al.,  1986).  ~25I-iodo- 
deoxyuridine-labeled BCE cells were grown for 72 h 
on the human amnion BM, and cell invasion was de- 
termined by measuring the radioactivity associated 
with the tissue after removal of the noninvasive cell 
layer.  BCE cells were noninvasive under normal con- 
ditions.  Addition of human bFGF to either the BM or 
to the stromal aspect of the amnion  induced BCE cell 
invasion with a dose-dependent response.  This effect 
was maximal  in the presence of 70 ng/ml bFGF, and 
was inhibited by anti-bFGF antibody.  Transforming 
growth factor beta, as well as plasmin  inhibitors and 
anti-tissue type plasminogen activator antibody 
inhibited BCE cell invasion.  The tissue inhibitor of 
metalloproteinases,  1-10 phenanthroline,  anti-type IV 
and anti-interstitial  collagenase antibodies had the 
same effect. On the contrary,  anti-stromelysin anti- 
body and Eglin,  an inhibitor of elastase,  were ineffec- 
tive.  The results obtained show that both the plasmino- 
gen activator-plasmin  system and specific collagenases 
are involved in the invasive process occurring during 
angiogenesis. 
T 
HE formation  of new capillaries  occurs in a variety of 
normal and pathologic  conditions,  including  embryo 
and  organ  development,  wound healing,  and tumor 
growth.  In the past few years a number of normal and tumor 
cells have been reported to produce polypeptide factors capa- 
ble of inducing  the formation  of capillaries  either in vitro 
and/or in vivo. Among the angiogenic  factors so far purified 
and  characterized,  basic fibroblast growth factor (bFGF)  ~ 
appears to be one of the more potent angiogenesis  inducers 
(Folkman,  1986; Gospodarowicz et al.,  1986; Lobb et al., 
1986; Schweigerer et al.,  1987). The response of microvas- 
cular endothelial  cells to bFGF in vitro consists of three ma- 
jor components:  an increase in the rate of cell proliferation, 
a stimulation  of endothelial  cell migration  along a gradient 
of angiogenic  factor, and an increased production of proteo- 
lytic enzymes such as plasminogen  activator  (PA) and col- 
lagenase  (Moscatelli et al.,  1986; Presta et al.,  1986). The 
production of proteinases by endothelial  cells is believed to 
be of fundamental  importance  for the degradation  of the 
perivascular extracellular  matrix and of the stroma of  the tis- 
1.  Abbreviations  used in  this paper:  BCE, bovine capillary  endothelial; 
bFGF, basic fibroblast growth factor; BM, basement membrane; DOC, Na- 
deoxycholate; PA, plasminogen activator; TGF/~, transforming growth fac- 
tor beta; tPA, tissue type plasminogen activator; uPA, urokinase plasmino- 
gen activator. 
sue  to  be  vascularized.  In  this  regard  microvascular  en- 
dothelial  cells appear to behave similarly  to invasive tumor 
cells in that they are able to cross the anatomical  barriers, 
basement membranes (BM), and interstitial  stroma that sep- 
arate the tissue compartments of the organism  (Mullins  and 
Rohrlich,  1983; Dane et al.,  1985; Moscatelli and Rifkin, 
1988). 
It has been proposed that during  angiogenesis,  as well as 
in tumor invasion,  a cascade of proteolytic events occurs, 
which leads to the degradation  of the extracellular  matrix 
(Gross et al., 1983; Mignatti et al., 1986). The PA produced 
by endothelial cells converts plasminogen to plasmin, a serine 
proteinase  with trypsin-like  specificity. Since the amount of 
plasminogen  present in most tissues is relatively  high,  the 
production of even small amounts  of PA may result in high 
levels of local plasmin  activity. Moreover,  while plasmin is 
capable  of degrading  major  extracellular  matrix  compo- 
nents, including fibronectin and laminin (Werb et al., 1980), 
recent evidence also points  to a central  role for plasmin in 
the activation of other enzymes. Although the importance of 
PAs in matrix  degradation  has been debated (Kramer et al., 
1982; Bogenman and Jones, 1983; Heisel et al., 1983; Berg- 
man et al.,  1986), a number of reports indicate that PA may 
catalyze the degradation  of collagen  through  the formation 
of plasmin,  which acts as an activator of the zymogen forms 
of collagenases  secreted by most cells (Werb et al.,  1977; 
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Gavrilovic et al., 1985). Endothelial cells have been reported 
to produce interstitial, as well as type IV collagenase (Ka- 
lebic et al.,  1983; Gross et al.,  1983).  Type IV collagenase 
degrades type IV collagen, the basement membrane colla- 
gen, and it has been shown that plasmin can activate type IV 
collagenase (Salo et al.,  1982).  Thus, the production of a 
proteinase with restricted specificity, such as PA, can result 
in the generation of several active proteinases: plasmin, with 
a  broad substrate specificity, and the collagenases,  whose 
spectrum is restricted. This array of proteinases can afford 
the degradation of and infiltration into the basement mem- 
brane by microvascular endothelial cells. 
However,  while  the  production  of  proteinases  by  en- 
dothelial cells in response to angiogenic factors has been 
documented, the role of enzymes in angiogenesis has not 
been demonstrated experimentally. This is mainly because of 
the lack of a simple and biologically relevant in vitro model 
for the capillary wall. The bioassays for angiogenesis used 
so far, neovascularization of the rabbit cornea (Gimbrone et 
al., 1974) or angiogenesis on the chick chorioallantoic mem- 
brane (Ausprunk et al.,  1975),  are cumbersome and non- 
quantitative.  Moreover, they have distinct drawbacks since 
host factors,  such as  those involved in  inflammation,  can 
influence the angiogenic response. 
Attempts have been made to develop in vitro angiogenesis 
assays.  Rat aortic rings cultured in plasma clot have been 
reported to give rise to a microvascular network consisting 
of branching  endothelial channels  (Nicosia et al.,  1983). 
Montesano  et al.  (1983)  have reported that capillary  en- 
dothelial cells grown on a three-dimensional type I collagen 
gel can invade into the culture substrate and form tube-like 
structures  resembling  capillaries.  This  phenomenon  has 
been referred to as "in vitro angiogenesis" and can be induced 
by treatment with tumor promoters or with bFGF  (Mon- 
tesano and Orci,  1985;  Montesano et al.,  1986). More re- 
cently, fibrin gels have also been used to study microvascular 
endothelial cell invasion and differentiation into structures 
resembling capillaries (Montesano et al.,  1987). These ex- 
perimental models provide relatively simple, but nonquan- 
titative,  in  vitro  assays  for  angiogenesis.  However,  the 
artificial conditions of the systems used are far from repre- 
senting  the environment in  which  angiogenesis occurs in 
vivo. The capillary basal lamina mainly consists of BM (type 
IV)  collagen,  which  is  distinct from interstitial collagens 
and whose degradation has very specific proteolytic require- 
ments (Yurchenco and Ruben, 1987). Moreover, several ma- 
jor glycoproteins, including fibronectin and laminin, as well 
as heparan sulfate proteoglycans are also present in the BM 
(Liotta et al.,  1983; Madri et al.,  1983). 
The BM of the human amnion has been used by other 
workers as a growth substrate for microvascular endothelial 
cells (Madri et al.,  1983;  Furie et al.,  1984). This model 
provides  experimental  conditions  that  are  close  to  those 
found in  vivo.  Under these conditions,  microvascular en- 
dothelial  cells  differentiate  spontaneously  into  tube-like 
structures resembling capillaries, although they do not in- 
vade through the BM (Madri et al., 1983; Furie et al., 1984). 
However, angiogenesis inducers were not used in these ex- 
periments, and the authors did not report whether the en- 
dothelial cells used spontaneously produced any of the pro- 
teinases  that  might  promote degradation  of and  invasion 
through the BM. 
We have recently described a quantitative in vitro assay for 
tumor invasion (Mignatti  et al.,  1986),  which consists  in 
determining  the  number  of  ~25I-iododeoxyuridine-labeled 
cells that infiltrate through the BM and invade into the under- 
lying stroma of the human amnion. We have now used the 
same experimental system to study invasion of the BM by bo- 
vine capillary endothelial (BCE) cells stimulated with bFGE 
The effects of synthetic and natural inhibitors of and antibod- 
ies to serine- and metalloproteinases were studied to under- 
stand the role of these enzymes in the invasive processes that 
occur during  angiogenesis.  The results  from this  in vitro 
study  indicate  that  bFGF  can  induce  microvascular  en- 
dothelial cells to invade through the amnion BM, and that the 
molecular mechanisms mediating this process involve a cas- 
cade of serine- and metalloproteinase activations similar to 
that observed for tumor invasion. 
Materials and Methods 
Cells and Media 
BCE cells were  isolated from the adrenal cortex of yearling calves and 
grown as previously described (Folkman et al.,  1979). The cells were rou- 
tinely subcultured at a  1:5 split ratio and grown to confluency in 100-ram 
gelatin-coated plastic petri dishes in DME supplemented with 5%  donor 
calf serum (growth medium). The BCE cells used in all the amnion assays 
described were derived from one clone and were used between passages 7 
and 14. 
Cell Labeling with u~l-lododeoxyuridine 
Subconfluent cultures of BCE cells, 2 d after trypsinization, were incubated 
at 37°C for  18 h  in the presence of 3.0 #Ci/ml of 125I-iododeoxyuridine 
(2,200 Ci/mmol; New England Nuclear, Boston, MA) in growth medium. 
At the end of the incubation the cultures were washed three times with 10 
ml of medium, trypsinized, and resuspended in 40 ml of growth medium. 
The cells were sedimented at 500 g  for 5  min and resuspended in fresh 
growth medium containing penicillin (1,000 U/ml), streptomycin sulfate (40 
mg/ml), and amphotericine B (Fungizone) (2.5 ~g/ml). 10-/~1  aliquots of the 
cell suspension, labeling medium, pooled washings, trypsin, and superna- 
rant after centrifugation were collected for determination of the radioactivity 
in a gamma counter (Packard Instrument Co., Inc., Downers Grove, IL). 
Cell concentration was determined using a  hemocytometer. Under these 
conditions the radioactivity associated with the cells was 20-45 % of the to- 
tal radioactivity in the labeling medium. The nonsedimentable radioactivity 
in the cell suspension was 0-1%, and the specific labeling, determined in 
27 experiments, was 1.98  +  0.16 cpm!cell. 
Assay for BCE Cell Invasion into the 
Human Amniotic Membrane 
Human amniotic  membranes were  isolated  from  fresh term  placentas, 
fastened to Teflon rings, and denuded of the epithelium as previously de- 
scribed (Mignatti et al., 1986). The membranes were stored at 4°C in DME 
supplemented with antibiotics and Fungizone (as above) and were always 
used within 1 wk after preparation. In each assay tissue obtained from only 
one placenta was used. The Teflon rings holding the amnion membrane were 
placed onto silicone rubber rings fastened to the bottom of 35-mm microtiter 
plastic  tissue culture  wells (Costar,  Data  Packaging Corp.,  Cambridge, 
MA) with sterilized nontoxic silicone lubricant (Dow Corning Corp., Mid- 
land, MI). The inner diameter of the silicone rubber rings (lower compart- 
ment) was filled with 500/.tl of growth medium containing antibiotics and 
Fungizone. The  125I-iododeoxyuridine-labeled BCE cell  suspension was 
added in the upper compartment of the amnion chamber in a final volume 
of I ml. In a typical assay, 1.5  x  105 BCE cells, corresponding to ",,3.0  x 
105 cpm 125I were added in each invasion chamber. 3 ml of growth medium 
containing antibiotics and Fungizone were pipetted into the tissue culture 
well (outer compartment) so that the level of fluid was the same inside and 
outside the Teflon ring and no hydrostatic pressure would be exerted on the 
amniotic membrane. When indicated, bFGF was added to the cell suspen- 
sion in the upper compartment, diluted in 10 pl of growth medium. When 
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Figure  1.  Correlation  between 
number of BCE cells seeded on 
the  amnion  BM  and  number  of 
BM-attached cells. The graph re- 
ports  data  combined  from  15 
experiments  in  which  z25I-iodo- 
deoxyuridine-labeled  BCE  cells 
were seeded on the amnion BM 
at the concentrations indicated, in 
the presence or in the absence of 
bFGE  In  most  experiments  70 
ng/ml  of  bFGF  were  added  in 
the lower chamber compartment 
as  described  in  Materials  and 
Methods. After 72 h incubation at 
37°C, the culture medium was re- 
moved and the distribution of ra- 
diolabeled  cells  determined  as 
described in Materials and Meth- 
ods. The radioactivity associated 
with  the  pooled  DOC  and  PBS 
washings is reported as percent of 
the  total  radioactivity  recovered 
in the invasion chamber. In the in- 
set,  the  radioactivity  present  in 
the culture  supernatant (medium 
in  the  upper  compartment)  of 
samples  run  in  the  absence  of 
bFGF is also reported as percent 
of  the  total  ~25I cpm  recovered 
in the invasion chamber.  As dis- 
cussed in Results, most of this ra- 
dioactivity was accounted for by intact cells and was not different in the presence or in the absence of bFGE  In both graphs each point 
represents the mean of triplicate samples. The curves were determined by a computerized statistical program. They all fit to a polynomial 
correlation with a  highly significant correlation coefficient (r  =  0.96; p  <  0.001). 
the growth factor was added in the lower compartment, it was diluted in 
growth medium to a concentration sevenfold higher than the concentrations 
added in the upper compartment, and 500 #1 were added inside the silicone 
rubber ring before seeding the cell suspension in the upper compartment. 
This was done to compensate for dilution when the 3 ml of growth medium 
were added in the outer compartment. The proteinase inhibitors and anti- 
bodies to be tested were diluted to a concentration fivefold higher than the 
final concentration indicated, and 200/~1 were incubated on the amnion BM 
for 1 h at room temperature. The cell suspension was then added in 800 
/zl of growth medium containing antibiotics and Fungizone. The tissue cul- 
ture plates were placed in a moist chamber and incubated at 37°C in a 5% 
CO2 atmosphere. After 72 h incubation the supernatant was removed and, 
after two washings with PBS, the cell layer was lysed in 0.5  ml of 4% 
Na-deoxycholate (DOC) and removed by carefully scraping with a rubber 
policeman. The tissue was washed three times with PBS, and the DOC and 
PBS washings were pooled in the same tube. The amnion was eventually 
detached from the Teflon ring, and the radioactivity associated with it, as 
well as that of the medium in the upper, lower, and outer compartments, 
the PBS, and the pooled DOC and PBS washings, was measured in a gamma 
counter. To determine the number of invasive cells, the 12sI cpm associated 
with the amnion in the presence of a 0.4/zm pore filter,  which account for 
background, cell-free radioactivity, were subtracted from the radioactivity 
associated with the amnion in the absence of the filter,  and the difference 
was divided by the specific cell labeling 0251 cpm/cell), as determined at 
the beginning of the assay. The amount of radioactivity associated with the 
membrane in the presence of the filter never exceeded 0.20% of the total 
cpm. Samples and controls were assayed in triplicate. 
bFGF Diffusion in the Amnion Invasion Chamber 
Two nanograms of 125I-labeled bFGF (4,500 cpm/ng; 70% TCA precipita- 
ble) were added either in the upper compartment or in the medium (500 
td) inside the silicone rubber ring in the lower compartment of amnion inva- 
sion chambers. Immediately after,  1.50  x  105 BCE cells were seeded in 
the upper compartment, and 3 ml of growth medium were added in the tis- 
sue culture well. At the end of incubation at 37°C, the medium in the tissue 
culture well was collected separately from the medium inside the silicone 
rubber ring, and the samples were processed as described above for amnion 
invasion assays. The media from the upper and lower compartments were 
TCA precipitated, and the radioactivity associated with them, as well as that 
of  the PBS and DOC washings and of  the amnion, was measured in a gamma 
counter. Triplicate samples were assayed. 
bFGF, Transforming Growth Factor Beta (TGF [3), 
Proteinase lnhibitors, and Antibodies 
The human bFGF was purified from human placenta as previously de- 
scribed (Moscatelli et al.,  1986).  Recombinant bFGE kindly provided by 
Synergen, Inc. (Boulder, CO), was also used in several experiments; its activ- 
ity in the amnion invasion assay was equivalent to that of the placental bFGE 
Anti-human bFGF IgG was precipitated with ammonium sulfate from rab- 
bit antiserum raised against pure antigen by Dr. J. Joseph-Silverstein (New 
York University Medical School). Transforming Growth Factor beta was a 
gift from Dr. O. Saksela (University of Helsinki, Finland). Rabbit anti-hu- 
man skin fibroblast collagenase antiserum was a gift from Dr. H. G. Welgus 
(Jewish Hospital, St. Louis, MO); purified anti-stromelysin and anti-type 
IV collagenase IgGs, previously shown to be monospecific (Wilhelm et al., 
1987; Collier et al., 1988), were a gift from Dr. G. I. Goldberg (Washington 
University Medical Center, St. Louis, MO); rabbit nonimmune and anti- 
human tissue type plasminogen activator IgGs were purified from serum by 
ammonium sulfate precipitation and DEAE chromatography. Recombinant 
tissue inhibitor of metalloproteinases was a gift from Synergen, Inc. (Boul- 
der, CO); Eglin was a gift from Dr.  H.  P. Schnabli (Ciba-Geigy, Basel, 
Switzerland); Erythrina trypsin inhibitor was a gift from Dr. E. L. Wilson 
(University of Cape Town,  South Africa).  1-10 phenanthroline, soybean 
trypsin inhibitor, epsilon aminocaproic acid, and leupeptin were purchased 
from Sigma Chemical Co. (St. Louis, MO). Trasylol ®  was a gift from Bayer 
Werk (Elberfeld, West Germany). 
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Figure 2.  Correlation  between the number of BM-attached BCE 
cells and the number of  cells that invade through the BM. The graph 
reports  the  data combined  from 16 independent  experiments  in 
which t25I-iododeoxyuridine-labeled BCE cells were added on the 
amnion BM at different concentrations,  0.25-1.70  x  10  ~ cells per 
invasion chamber, and in the absence or in the presence of 70 ng/ml 
bFGF added in the lower compartment.  After 72 h incubation at 
37°C, samples and controls were treated as described in Materials 
and  Methods.  For determination  of the number of BM-attached 
cells, the radioactivity associated with the pooled DOC and PBS 
washings was divided by the specific cell labeling, after subtraction 
of the  t25I cpm associated  with the  DOC  plus PBS washings of 
control samples in which a 0.4-/~m filter prevented cell attachment on 
the amnion BM. The number of invasive cells was determined as 
described  in  Materials  and  Methods.  Each  point  represents  the 
mean of triplicate samples. The curve was determined by a com- 
puterized statistical program. It fits to a polynomial correlation with 
a highly significant correlation coefficient (r = 0.86; p < 0.001). No 
significant correlation could be evidenced for the data obtained in 
the absence of bFGE [], 70 ng/ml bFGF;  ,, control. 
Results 
Characterization of  BCE Cell Invasion into the 
Human Amniotic Membrane 
Under  the  culture  conditions  described  in  Materials  and 
Methods,  the  BCE  cells  grown  on  gelatin-coated  dishes 
reached a density of 7.5  x  104 cells/cm  2.  When confluent 
cultures were split 1:5, virtually 100% of the cells spread on 
the substrate and were usually confluent in 5-6 d. When 1.5 
x  104 BCE cells/cm  2 (corresponding to a confluent culture 
split 1:5) were seeded on the amnion BM, they spread rap- 
idly and acquired a spindle-shaped morphology, but within 
24 h after seeding most of the cells were found floating in 
the medium. However, when higher numbers of cells were 
added onto the amnion,  their attachment was more stable. 
This observation was confirmed when ~zsI-iododeoxyuridine- 
labeled BCE cells were used. After 72 h incubation, the cells 
attached on the amnion BM were removed by lysis with 4 % 
DOC and scraping with a rubber policeman, as described in 
Materials and Methods. The percent of the total applied ra- 
dioactivity associated with  the DOC  and  subsequent PBS 
washings provided a measurement of the number of cells that 
were attached  on the BM.  Fig.  1 shows a  compilation of 
results obtained in different experiments in which the cells 
were  seeded  at different  densities.  The percent  of DOC- 
removed radioactivity correlated with the number of cells 
added  onto  the  amnion  BM.  The  correlation  was  highly 
significant (p <  0.001) and showed that the percent of BM- 
attached cells increased for cell densities ranging from 2.25 
x  104 to  1.50  ×  1@ cells per invasion chamber (2 cm2). 
For higher cell densities, corresponding to overconfluence, 
the slope of the regression line leveled off and then tended 
to become negative. This indicated that under these condi- 
tions the number of cells that remained stably attached to the 
amnion BM increased with increasing the cell density, and 
decreased  when  the  cells  were added  at a  density  corre- 
sponding to overconfluence. The maximum radioactivity as- 
sociated with the DOC washing was 70-75 % of the total J25I 
input. As the radioactivity removed by DOC increased, the 
percent of radioactivity in the medium of the upper compart- 
ment decreased (Fig.  1, inset). 60-70% of this radioactivity 
was sedimentable, indicating that it primarily represented in- 
tact cells. Addition of bFGF in the upper or in the lower com- 
partment of the invasion chamber did not significantly affect 
cell attachment. As shown in Fig. 1, the correlation lines be- 
tween the number of cells seeded and the percent of radioac- 
tivity removed by DOC in the presence and in the absence 
of bFGF were superimposable. 
We then verified whether the BCE cells were able to invade 
into the amnion stroma by measuring the radioactivity as- 
sociated with the membrane after the attached ceils had been 
removed. To measure possible contamination of the mem- 
brane by cell-free radioactivity liberated during cell lysis and 
subsequent scraping of the amnion BM,  ~2q-iododeoxyuri- 
dine-labeled BCE cells were grown in control chambers on a 
0.4-#m pore polyester filter placed on the membrane surface. 
As was previously described,  the filter prevented the cells 
from invading but was permeable to soluble cellular compo- 
nents (Mignatti et al.,  1986).  By this method, the number 
of cells remaining in the amnion stroma after the quantitative 
removal of the cells growing on the BM could be determined 
as described in Materials and Methods.  The value obtained 
for the number of cells present in the amnion stroma gave 
a lowest estimate, and would differ from the actual number 
of invasive cells depending on the decrease in specific activ- 
ity caused by cell growth. As shown in Fig. 2, significant am- 
nion  invasion by the  BCE cells could be detected by this 
method. Invasion depended on the presence of bFGF, and the 
number of invasive cells was a function of the number of cells 
attached to the amnion  BM.  In the  presence of 70 ng/ml 
bFGF in the lower compartment, the estimated number of in- 
vasive cells after 72  h  incubation  increased from 300 per 
chamber to >2,000 per chamber, when the cell density in- 
creased from 3.20  x  104 to  1.50  ×  l0  s cells per chamber. 
This is approximately the same proportion of cells found to 
be invasive when B16/BL6, an invasive mouse melanoma cell 
line, was previously examined (Mignatti et al., 1986).  On the 
contrary, in the absence of bFGF the estimated number of 
BCE cells in the amnion stroma never exceeded 70-120 at 
all cell densities.  The correlation between the  number of 
BM-attached and invasive cells in the presence of bFGF was 
highly significant (p <  0.001).  In the absence of the growth 
factor no significant correlation was evident. These results 
indicated that (a) BCE cell attachment to the amnion BM de- 
pended on the density at which the cells were added in the 
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A 
Experimental  conditions  Experiment  1  Experiment 2  Experiment 3 
N.  seeded cells  150,000  150,000  155,000 
~25I cpm/cell  2.77  1.56  1.29 
Total  ~2sI cpm*  378,521  5- 28,389  223,846  5-  15,445  185,954 5-  13,575 
B 
]2sI cpm~;  N.  invasive  ~:~1 cpm;  ~  N.  invasive  ~25I cpm~  N.  invasive 
Additions  (mean +  SD)  cells§ (mean)  (mean  +  SD)  cells§ (mean)  (mean  +  SD)  cells§ (mean) 
0.4 #m filter  567  +  251  0.0  358  +  67  0.0  503  +96  0.0 
None  785  +  283  78.7  493  +  22  86.5  589 5- 48  86.7 
bFGF 10 ng/ml 
in upper comp.  2,638  5- 440  747.7  1,366 5- 45  646.2  1,571  5- 227  827.9 
bFGF 70 ng/ml 
in lower comp.  5,698  5- 525  1,852.5  3,483  5- 347  2,003.7  2,762  +  157  1,751.2 
BCE cells were metabolically labeled with  ~2ff-iododeoxyuridine, as described  in Materials and Methods, and the specific cell labeling was determined  by cal- 
culating the ratio between ~25I cpm/ml of washed cell suspension and number of ceils per milliliter as determined in a hemocytometer.  The cells were then seeded 
on the amnion BM at the concentrations  indicated. Details for addition of bFGF and computation of the number of invasive cells are described in Materials and 
Methods.  Samples and controls  were assayed in triplicate.  The results obtained in three independent experiments are reported. 
* Total t25I cpm recovered per invasion chamber, calculated by summing the radioactivity present in upper and lower chamber medium, PBS and DOC plus PBS 
washings,  amnion membrane,  and polyester  filter (when present).  Mean  :i:  SD is reported. 
~: Amnion-associated radioactivity  after DOC treatment,  scraping,  and PBS washings. 
§ Estimated number of invasive cells,  calculated as reported  in Materials and Methods. 
invasion chamber and was not affected by bFGE and (b) BCE 
cell invasion through the amnion BM depended both on the 
cell number and on the presence of bFGE and was maximal 
when the cells on the BM were confluent. The latter condi- 
tion was attained  when  1.50  x  105 BCE cells were added 
onto the amnion BM.  Under these experimental  conditions 
the results obtained by the assay appeared very reproducible. 
As shown in Table I, the calculated number of cells present 
in the amnion stroma after 72 h incubation was comparable 
in different experiments, regardless of the specific cell label- 
ing at the beginning of the assay and of the total ~25I cpm in- 
put in the invasion chamber. 
The effect of bFGF on BCE cell invasion into the amniotic 
membrane was dose dependent,  regardless  of whether the 
growth factor was added in the upper or in the lower com- 
partment  of the  invasion  chamber.  As  shown  in  Fig.  3, 
1.0-2.5  x  10s cells per chamber,  invaded into the amnion 
in the presence of 10-70 ng/ml bFGE As described in Mate- 
rials and Methods, excess bFGF was added in the lower com- 
partment to compensate for dilution in the total volume of 
medium.  Experiments done with  t2SI-labeled  bFGF showed 
that the growth factor diffused very rapidly through the am- 
niotic membrane. As shown in Fig. 4, equilibrium between 
the upper and lower compartments was reached after 24 h 
incubation, either when bFGF was added in the upper com- 
partment (Fig. 4 a) or when bFGF was added in the lower 
compartment (Fig. 4 b). In the latter case, the concentration 
gradient obtained between the two compartments during the 
initial  24 h  of the assay was steeper than when bFGF was 
added in the upper compartment. This was probably because 
the initial bFGF concentration in the lower compartment was 
twice  as  high  as  in  the  upper  compartment  (4  ng/ml  vs. 
~o  a  U 
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0.0  0.01  0.1  1.0  10.0 
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0-07  0.7  ZO  70.0 
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Figure 3. Dose-dependent stimulation  of BCE cell 
amnion invasion by bFGF added in the upper or 
in the lower compartment of  the invasion chamber. 
(a) bFGF added in the upper compartment: the 
growth factor was addded immediately after seed- 
ing  the  ~25I-iododeoxyuridine-labeled  BCE  cell 
suspension.  (b) bFGF added in the lower compart- 
ment: the growth factor was added in the lower 
compartment of  the invasion chamber as described 
in Materials  and Methods. The two experimental 
conditions  were tested in parallel  assays in which 
1.5  x  105  t2sI-iododeoxyuridine-labeled  BCE 
cells  were added on the amnion BM. After 72 h 
incubation  at  37°C  the  samples  were processed 
and the number of invasive cells per invasion cham- 
ber was determined  as described in Materials  and 
Methods.  Mean and standard error of  three experi- 
ments  are shown. 
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Figure 4. Diffusion of ~2SI-labeled 
bFGF through the amniotic mem- 
brane  and  BCE cell  layer. Two 
nanograms of t25I-labeled bFGF 
(4,500  cpm/ng) were added ei- 
ther in the upper compartment (a) 
or in the medium (500/zl) inside 
the  silicone rubber  ring in  the 
lower compartment (b) of amnion 
invasion chambers. Immediately 
after, 1.50 ×  lO  s BCE cells were 
seeded in the upper compamnent, 
and 3 ml of growth medium were 
added in the tissue culture well. 
The chambers were incubated at 
37°C and at the time points indicated, the medium in the different compartments was collected, TCA precipitated, and the radioactivity 
measured in a gamma counter. Each point represents the mean of triplicate samples. A, upper compartment; e, lower compartment; L 
outer compartment. 
2 ng/ml, respectively). The bFGF associated with the BCE 
cell layer and the amnion under either condition of addition 
accounted for 5-10% of the total bFGF input.  On the con- 
trary, the bFGF diffusing into the outer compartment repre- 
sented no more than 15 % of the amount of bFGF remaining 
inside the lower compartment and accounted for •3  % of the 
total bFGF input. 
As shown in Fig. 5 the effect of bFGF was neutralized by 
a  specific rabbit anti-human bFGF IgG but not by nonim- 
mune rabbit IgG. Moreover, the stimulation of BCE cell in- 
vasion was  reproduced using recombinant bFGF made in 
Escherichia  coli,  thereby demonstrating that the effect  re- 
sulted from the action of bFGF and not from a contaminant. 
Phase contrast microscopy provided further evidence of 
the effect of bFGF on the BCE cells grown on the amnion 
BM. BCE cells grown at high density on this substrate ap- 
peared to form a regular monolayer of closely apposed elon- 
gated cells (Fig.  6 a). After 72 h incubation in the presence 
of 70 ng/ml bFGF in the lower compartment,  some cells 
showed a more irregular morphology, with branching pro- 
cesses criss-crossing the regularly oriented monolayer (Fig. 
6 b). While no cells were visible in the stroma in the absence 
of bFGF (Fig.  6 c), refractile elongated cells could be seen 
dispersed in the irregular array of the stromal collagen fibers 
below the BM (Fig.  6 d).  Due to the extreme thickness of 
the bndothelial cell layer and underlying amnion, however, 
the precise nature of these structures was not clear.  Occa- 
sionally,  when cut edges of the amnion were examined by 
scanning electron microscopy, very long tube-like structures 
could be seen in the stroma. These structures,  which were 
several  hundred micrometers in length and appeared to be 
multicellular,  may represent capillary-like sprouts invading 
through the stroma. However, they were not found reproduc- 
ibly,  and their formation may require specific conditions. 
Effect of the TGF f3 on BCE Cell Invasion through 
the Amnion BM 
TGF  fl has  been  reported  to  inhibit  collagenase and  uro- 
kinase plasminogen activator (uPA) activities in different cell 
types,  including BCE cells,  by decreasing the synthesis of 
these  enzymes and  simultaneously  stimulating  TIMP and 
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Figure 5.  Inhibition of bFGF-in- 
duced BCE cell amnion invasion 
by anti-bFGF antibody. 70 ng/ml 
of bFGF were added in the lower 
compartment as described in Ma- 
terials and Methods. Purified an- 
ti-human  bFGF  or  nonimmune 
rabbit IgG were preincubated on 
the BM as described in Materials 
and Methods. The concentrations 
indicated are the concentrations 
in  the  final volume of medium 
(1 ml)  after addition of the  cell 
suspension. After 72 h incubation 
at  37°C samples and  controls 
were processed and the number of 
invasive cells per invasion cham- 
ber was determined as described 
in Materials and Methods. Mean 
and  standard error  of three ex- 
periments are shown. 
The Journal of Cell Biology, Volume 108,  1989  676 Figure 6. Morphology of BCE cells grown on the amnion BM.  150,000 BCE cells were seeded on the amnion BM in the absence or in 
the presence of 70 ng/ml bFGF aded in the lower chamber compartment as described  in Materials and Methods.  After 72 h incubation 
at 37°C the cultures were photographed with an inverted phase contrast microscope focusing at different depths. (a) Cells in the absence 
of bFGF; focus on the cell layer. (b) Cells in the presence of bFGF; focus on the cell layer. (c) Cells in the absence of bFGF; focus in 
the stroma.  (d) Cells in the presence  of bFGF; focus in the stroma.  Bars,  10 #m. 
type 1 PA inhibitor (PAl-l) production (Sporn et al.,  1986; 
Lahio et al., 1986a, Edwards et al., 1987; Lund et al.,  1987; 
Saksela et al.,  1987).  Moreover, it has also been shown to 
inhibit the proliferation and motility of BCE cells and to pre- 
vent their  invasion  into  collagen  matrices  (Muller  et  al., 
1987).  It was, therefore,  of interest to test whether TGF 
inhibited BCE cell invasion into a more complex structure, 
such as the amniotic membrane.  TGF/3 was added in the 
medium of the upper compartment after the cells had been 
seeded on the BM and stimulated to invade through the addi- 
tion of 70 ng/ml bFGF in the lower compartment. As shown 
in Fig.  7, TGF/3 had a dose-dependent inhibitory effect on 
BCE cell invasion.  1 and 10 ng/ml prevented tissue invasion, 
whereas  0.1  ng/ml  was  ineffective.  At  the  concentrations 
tested, TGF/3 did not appear to be cytotoxic nor to interfere 
with cell attachment to the amnion BM, as judged from the 
amount of radioactivity recovered in the medium of the up- 
per compartment compared to that of the control chambers. 
Effect of  Proteinase Inhibitors on BCE Cell Invasion 
through the Amnion BM 
It has been proposed that during angiogenesis, as well as in 
tumor invasion, the proteinases produced by the cells play a 
central role in the degradation of and infiltration into the BM 
by invasive cells (Gross et al.,  1983;  Mullins and Rohrlich, 
1983;  Dane et al.,  1985;  Mignatti et al.,  1986;  Moscatelli 
and Rifldn,  1988).  To test this hypothesis we used the assay 
described above and attempted to inhibit selectively specific 
enzymes with either pure proteinase inhibitors or antibodies. 
Since bFGF is known to stimulate collagenase and PA pro- 
duction by BCE cells (Moscatelli et al.,  1986; Presta et al., 
1986),  attention was focused on these proteinases.  150,000 
~25I-iododeoxyuridine-labeled BCE cells were added on the 
amnion BM and stimulated to invade by the addition of 70 
ng/ml bFGF on the stromal aspect of the tissue. To facilitate 
enzyme-inhibitor interactions at the cell substratum contact 
sites,  the  proteinase inhibitors  and antibodies were pread- 
sorbed on the amnion BM for 1 h  at room temperature, as 
described in Materials and Methods. 
The role of serine proteinases in BCE cell invasion was 
studied by using inhibitors of plasmin. These included apro- 
tinin  (trasylol),  soybean trypsin  inhibitor,  epsilon  amino- 
caproic acid (EACA), Erythrina trypsin inhibitor, a natural 
inhibitor of the tissue type plasminogen activator (tPA)  that 
also inhibits plasmin (Heussen et al.,  1984), and leupeptin, 
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Figure 7.  Dose-dependent inhibition of bFGF-induced BCE cell 
amnion invasion by TGF/L 70 ng/ml of bFGF were added in the 
lower chamber compartment as described in Materials and Meth- 
ods, before seeding 1.50 ×  105 t25I-iododeoxyuridine-labeled  BCE 
cells in the upper compartment. In addition, control medium or the 
indicated concentrations of TGF/3 were added to the cell suspen- 
sion in 10 ttl of growth medium immediately after seeding. After 
72 h incubation at 37°C samples and controls were processed as 
described in Materials and Methods. The number of invasive cells 
per invasion chamber was estimated as described in Materials and 
Methods. Mean and standard error of three experiments are shown. 
an inhibitor of serine and cysteine proteinases. Anti-human 
tPA-purified IgG, which inhibited bovine tPA, was also tested. 
Moreover, Eglin was used in these experiments as an inhibi- 
tor of elastase. As shown in Fig.  8,  the plasmin inhibitors 
tested inhibited amnion invasion by the BCE cells. Interest- 
ingly,  the soybean trypsin inhibitor was not as effective as 
trasylol,  EACA,  and the  Erythrina inhibitor,  and did not 
completely inhibit BCE cell invasion at a concentration that 
inhibited  100%  of the plasmin generated by BCE cells in 
vitro (data not shown). Leupeptin, on the contrary, was to- 
tally ineffective. The failure of leupeptin to block cell inva- 
sion has been described earlier using mouse melanoma cells 
(Mignatti et al.,  1986;  Persky et al.,  1986)  and probably 
results from the low affinity of this inhibitor for plasmin. The 
anti-tPA IgG also prevented BCE cell invasion. On the con- 
trary, Eglin as well as nonimmune serum and IgG were in- 
effective. None of these inhibitors and antibodies increased 
the amount of radioactivity in the cell supernatant above con- 
trol values. Therefore, their inhibitory activity was not due 
to a cytotoxic effect nor to interference with BCE cell attach- 
ment to the amnion BM. 
We then studied the role of metalloproteinases in BCE cell 
invasion by testing the effect of metalloproteinase inhibitors 
and/or anti-collagenase antibodies. The reagents tested in- 
cluded 1-10 phenanthroline, recombinant tissue inhibitor of 
metalloproteinases, an anti-human skin fibroblast interstitial 
collagenase antiserum, anti-basement membrane (type IV) 
collagenase  (Collier  et  al.,  1988),  and  anti-stromelysin 
purified IgGs. At the concentrations indicated, none of these 
reagents appeared to be cytotoxic or appeared to prevent 
BCE cell attachment to the BM. Only in the presence of 1-10 
phenanthroline was the amount of radioactivity in the cell su- 
pernatant higher than in control chambers (•40  vs. 20% of 
the total cpm, respectively). Most of this radioactivity was 
sedimentable,  indicating  that  this  reagent  interfered with 
BCE cell attachment to the amnion BM. As shown in Fig. 
9  each of the  metalloproteinase inhibitors and  antibodies 
tested, except the anti-stromelysin IgG, was able to totally 
block BCE cell invasion into the amnion. Nonimmune serum 
and IgG were ineffective. 
Discussion 
The formation of new capillaries consists of several compo- 
nents, including cell multiplication at the base of the sprout- 
ing vessel, local degradation of the capillary basal lamina, 
migration of endothelial cells into the surrounding stroma, 
and the eventual differentiation of the migrated cells into 
mature microvessels (Ausprunk et al.,  1975; Ausprunk and 
Folkman,  1977;  Folkman,  1986).  bFGF has been  shown 
to stimulate all of these components of angiogenesis (Mosca- 
telli et al.,  1986;  Presta et al.,  1986).  In this process the 
degradation of the basal  lamina  is  of central importance, 
since it permits endothelial cell infiltration into the surround- 
ing stroma and migration towards the source of the angio- 
genic inducer. The basal lamina does not contain preformed 
channels that could afford cell migration, and in most cases 
angiogenesis initiates in the absence of any discontinuity in 
the tissue. Thus capillary endothelial cells must degrade the 
BM to infiltrate into the surrounding tissue.  The complex 
structure and composition of the microvascular extracellular 
matrix suggest that multiple and highly specialized cell func- 
tions are required for its degradation. Endothelial cells have 
been shown to produce enzymes capable of degrading ex- 
tracellular matrix proteins (Kalebic et al., 1983; Laug et al., 
1985; Pepper et al.,  1987). The analysis of this process in 
vivo, under the experimental conditions of most angiogene- 
sis assays,  is difficult and attempts have been made to estab- 
lish in vitro angiogenesis assays (Nicosia et al.,  1983; Laug 
et al.,  1985; Montesano and Orci,  1985,  1987; Montesano 
et al.,  1983,  1986,  1987).  Microvascular endothelial cells 
cultured on the human amnion BM provide an in vitro model 
for the capillary wall. Under these relatively defined condi- 
tions, BM degradation and endothelial cell infiltration into 
the interstitial stroma can be analyzed without the interfer- 
ence of host factors. 
The experiments presented in this paper have revealed sev- 
eral features of BCE invasion of the amnion. First, cell inva- 
sion was dependent on cell density and appeared to be maxi- 
mal  under optimal  conditions  for cell attachment.  While 
BCE cells can be grown at low densities on gelatin-coated 
The Journal of Cell Biology,  Volume 108, 1989  678 Soybean 
Erythrlna 
Control  medium 
bFGF  70 ng/ml 
Trusylol  200 U/ml 
SACA  SO0 ~,./ml 
Trypsin  Inh.  lO0~l~g/ml 
Loupoptln  I00 •g/ml 
Trypsin  |nh.  10 4  M 
Eglin  tO #S/re' 
Non-immune  IgG  300jllg/ml 
Anti- tPA  IgG  20~140/m  I 
I 
I 
I  , 
I 
1.0 
Invasive  cells 
I 
2J0 
x  lO -~ 
Figure  8.  Effect  of  serine-proteinase  inhibitors  and 
anti-plasminogen activator antibodies on bFGF-induced 
BCE cell amnion invasion. 70 ng/ml of  bFGF were added 
in the lower compartment as described in Materials and 
Methods. In addition, control medium or the inhibitors 
and IgGs indicated were preincubated on the amnion BM 
as described in Materials and Methods, before seeding 
1.50  x  l0  s  i25I-iododeoxyuridine-labeled BCE  cells. 
After 72 h incubation at 37°C samples and controls were 
processed and the number of invasive cells per invasion 
chamber was determined as described in Materials and 
Methods. Mean and standard error of five experiments 
are shown. 
plastic dishes, stable attachment and spreading on the am- 
nion BM appeared to be directly proportional to the density 
at which the cells were seeded. Perhaps, the cell-to-cell con- 
tact achieved at high cell density is more representative of 
the conditions in the vessel wall and is more inductive for 
certain cellular responses than when cells are at low densi- 
ties. Cell morphology appeared different on the amnion BM 
than on gelatin-coated dishes. These morphological changes 
may  indicate  an  important  role  for  BM  components  in 
modulating BCE cell behavior.  Previous data have shown 
that the growth rate of these cells depends on the type of col- 
lagen on which they are grown, and that on basement mem- 
brane  (type  IV)  collagen  microvascular  endothelial  cells 
differentiate into tube-like structures (Madri  et al.,  1983; 
Montesano et al., 1983). Second, BCE cell invasion was de- 
pendent upon the addition of bFGF to the amnion assay.  In 
the absence of bFGF essentially no cells were found in the 
amnion. Addition of bFGF to the cell supernatant or to the 
stromal aspect of the amnion induced invasion in a  dose- 
responsive manner, the bFGF diffusion experiments showed 
that bFGF, with a molecular mass of 18 kD, readily perme- 
ates the human amniotic membrane, which has a molecular 
mass cut-off of 60 kD (Liotta et al.,  1980). Third, invasion 
required the activities of both serine- and metaUoproteinases. 
The  results  obtained  with  serine  proteinase  inhibitors 
point to a central role for plasmin in BCE cell invasion. Inhi- 
bition  of  plasmin  activity  or  plasmin  formation  totally 
blocked amnion invasion. However, not all of the plasmin in- 
hibitors tested showed the same inhibitory effect on BCE cell 
invasion.  Soybean trypsin inhibitor was not as effective as 
EACA, trasylol, or the Erythrina trypsin inhibitor, whereas 
leupeptin was totally ineffective. While soybean trypsin in- 
hibitor, EACA, and trasylol have been shown to inhibit tumor 
cell invasion, the failure of leupeptin in blocking invasion has 
also been reported in other experimental systems (Mignatti 
et al., 1986; Persky et al., 1986). A possible explanation for 
the lack of inhibitory activity by these two inhibitors may be 
that they inhibit plasmin less effectively than other specific 
inhibitors under the experimental conditions used. To effec- 
tively block invasion, inhibition of proteinase activity must 
occur locally at cell substratum contact sites.  Recent data 
have shown the presence of cell surface receptors for PAs and 
plasminogen (Quigley,  1976; Hoal et al.,  1983; Bajpai and 
Baker,  1985;  Miles and Plow,  1985;  Vassalli  et al.,  1985; 
Plow et al.,  1986;  Stoppelli et al.,  1986;  Pfll~inen  et al., 
1988). The enzymes bound to their specific receptors appear 
to be at least partially protected from inactivation by pro- 
teinase  irdaibitors  (Chapman  et  al.,  1982;  Chapman  and 
Stone, 1984; Knudsen et al., 1986; Plow et al., 1986)..Natu- 
ral inhibitors have been shown to bind to extracellular matrix 
and to be active in this form (Laiho et al.,  1986;  Knudsen 
et al.,  1987; Levin and Santell, 1987; Mimuro et al.,  1987; 
P6ll/inen et al.,  1987). Therefore, complex interactions oc- 
cur at the sites of proteolysis by invading cells. Invasion of 
collagen or fibrin gels by PMA-stimulated BCE cells has 
been shown not to require plasmin activity (Montesano and 
Orci,  1985; Montesano et al.,  1987). The interpretation of 
these results is limited by the artificial conditions of the sys- 
tems used. The amnion BM consists of a complex array of 
substrates,  including several major glycoproteins, such as 
fibronectin and laminin, and heparan sulfate proteoglycans. 
Plasmin may play a central role in the degradation of these 
substrates, as well as in the activation of procollagenase(s). 
The results obtained using anti-tPA IgG raise an interest- 
ing question as to the proteolytic requirements for plasmino- 
gen activation by BCE cells. Capillary endothelial ceils have 
been reported to produce only tPA in vivo, and both tPA and 
uPA  upon  passaging  in  culture  (Kristensen  et al.,  1984; 
Levin and  Loskutoff,  1982;  Moscatelli,  1986;  Van  Hins- 
bergh,  1987). The clone of BCE cells we used in these ex- 
periments was  shown by zymography to produce both uPA 
and tPA. The former was prevalent in cell extracts, whereas 
cell-conditioned  medium  contained  only  tPA  (data  not 
shown). While we were able to demonstrate a requirement 
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Figure 9. Effect of metalloproteinase inhibi- 
tors  and  anti-collagenase  antibodies on 
bFGF-induced BCE cell amnion invasion. 
Experimental conditions were the same as 
described in the legend to Fig. 8. Mean and 
standard  error  of  five  experiments  are 
shown. 
for tPA by the use of anti-human tPA antibodies that cross 
react with bovine tPA, we were unable to do the identical ex- 
periment for uPA since the neutralizing potential of anti-hu- 
man uPA antibodies for bovine uPA is weak. This limited our 
investigation of the potential role of the uPA produced by 
BCE cells in amnion invasion. A more complete description 
of this process will require the availability of selective an- 
tisera against bovine uPA, as well as a better understanding 
of the activities of PAs in solid substrate assays such as the 
amnion. Regardless of this limitation, our results stress the 
importance of the PA-plasmin system in BCE cell invasion 
of the BM. 
The data obtained using metalloproteinase inhibitors also 
demonstrated a role for these enzymes in amnion invasion 
by BCE cells. Recombinant tissue inhibitor of metaUopro- 
teinases, as well as 1-10 phenanthroline, prevented the BCE 
cells from invading into the amnion.  Moreover, the colla- 
genolytic requirements for BCE cell invasion appear to be 
very specific. Anti-type IV and anti-interstitial collagenase 
antibodies completely prevented amnion invasion.  On the 
contrary, anti-stromelysin antibody was ineffective, as was 
Eglin,  an inhibitor of elastase.  While stromelysin can de- 
grade several BM and stromal components, including type 
IV collagen, fibronectin and laminin (Wilhelm et al., 1987), 
and certain elastases can degrade collagen(s) in its nonhelical 
structure (Mainardi et al., 1980; Pipoly and Crouch, 1987), 
these enzymes do not appear to be crucial for BM invasion 
by BCE cells. Stromelysin has recently been shown to acti- 
vate procollagenase in vitro (Murphy et al., 1987). The fail- 
ure of anti-stromelysin antibody to inhibit BM invasion indi- 
cates  that  in  this  experimental  model  other  pathways  of 
procollagenase activation may be effective. 
The inhibition of invasion obtained with anti-type IV col- 
lagenase makes an interesting point as to the importance of 
this enzyme in invasive processes. Type IV collagen is the 
major protein component ofBMs (Liotta et al., 1983; Madri 
et al.,  1983; Yurchenco and Ruben, 1987), and its degrada- 
tion appears to play a central role in cell invasion. However, 
complete inhibition of BCE cell invasion was also obtained 
by anti-interstitial collagenase antibody.  While this  effect 
may be explained by a limitation of the assay,  in that cells 
located superficially in the amnion may be removed by DOC 
lysis and scraping, it also points to the potential importance 
of interstitial collagenases in tissue invasion. Cells that have 
degraded the BM may in fact be unable to invade into the 
stroma if they lack specific degradative enzymes for intersti- 
tial collagens. 
Thus,  the  invasive  process  that  occurs  during  bFGF- 
stimulated  BCE  cell  invasion of the  human  amnion  BM 
requires  the  coordinated action  of both  the  plasminogen 
activator-plasmin system and of specific collagenases. The 
question arises whether the inhibitory effect of proteinase in- 
hibitors is due to inhibition of cell motility or to inhibition 
of matrix  degradation.  Recent unpublished  data  obtained 
with the migration assay described by Sato and Rifkin (1988) 
have shown little or no effect of several serine- and metal- 
loproteinase inhibitors on capillary endothelial cell migra- 
tion in vitro (Sato, Y., and D. B. Rifkin, personal communica- 
tion). We can then conclude that the inhibition of capillary 
cell invasion by proteinase inhibitors is due to inhibition of 
extracellular matrix degradation. 
The invasive process that occurs during angiogenesis'has 
several features in common with tumor invasion. With both 
cell types it was found that -,1-2 % of the cell population is 
able to invade through the amnion basement membrane in 
the invasion assay described (Mignatti et al.,  1986). How- 
ever, while tumor cells appear to be spontaneously invasive, 
capillary endothelial cells require the action of  an angiogene- 
sis  factor,  such  as  bFGF.  Both  tumor  and  capillary  en- 
dothelial cells use a cascade of proteolytic enzymes for this 
process, which involves the coordinated action of  both serine 
and metalloproteinases. We have previously shown that B16 
mouse melanoma cells use uPA to initiate this proteolytic 
cascade, while capillary endothelial cells appear to use tPA. 
However, the final product, plasmin, is the same in both sys- 
tems. Thus, the invasive mechanisms of tumor ceils appear 
The Journal of Cell Biology,  Volume  108, 1989  680 not to be unique to the neoplastic state but rather represent 
the inappropriate expression of normal functions that may be 
shared by a variety of invasive cells. Since pericellular pro- 
teolysis is rigorously controlled via extracellular proteolytic 
inhibitors and enzyme-binding sites, it will be of interest in 
the future to establish how these additional control mecha- 
nisms may modify cell invasion. 
The authors thank Heide Plesken, Melinda Vassallo, and Mirella Bensi for 
the excellent  technical  assistance. We are indebted to Dr. D. Moscatelli  for 
kindly  providing t2~l-labeled bFGF and for critically reading the manuscript. 
This work was supported by grants from the National Institutes of Health 
to D. B. Rifkin, and from the Italian Association for Cancer Research to P. Mig- 
natti. In the summer of 1987, P. Mignatti was granted an International Cancer 
Research Technology Transfer study grant by the International Union Against 
Cancer  for a short-term project  in D. B. Rifkin's laboratory. 
Received for publication  12 May  1988 and in revised form 18 October  1988. 
References 
Ausprunk,  D.  H., and J.  Folkman.  1977. Migration and proliferation  of en- 
dothelial cells in preformed and newly formed blood vessels during tumor 
angiogenesis.  Microvasc.  Res.  14:53-65. 
Ausprunk,  D. H., D. R. Knighton, and J. Folkman.  1975. Vascularization of 
normal and neoplastic tissues grafted into the chick chorioallantois.  Am. J. 
Pathol.  79:597-618. 
Bajpai, A., and J.  B. Baker.  1985. Cryptic  urokinase binding sites on human 
foreskin  fibroblasts. Biochem.  Biophys.  Res.  Commun.  133:475-482. 
Bergman, B. L., R. W. Scott, A. Bajpai, S. Watts, and J. B. Baker.  1986. Inhi- 
bition of tumor-cell mediated extracellular matrix destruction by a fibroblast 
proteinase inhibitor,  protease nexin. Proc. Natl. Acad.  Sci. USA. 83:996- 
1000. 
Bogenman, E., and P. A. Jones.  1983. Role of plasminogen in matrix degrada- 
tion by neoplastic cells. J.  Natl. Cancer Inst. 71:1177-1182. 
Chapman, H. A., and O. L. Stone, Jr_ 1984. Cooperation between plasmin and 
elastase in elastin degradation by intact murine macrophages.  Biochem. J. 
222:721-728. 
Chapman,  H. A., Z. Vavrin, and J. B. Hibbs.  1982. Macrophage fibrinolytic 
activity: identification of two pathways of plasmin formation by intact cells 
of a plasminogen activator  inhibitor.  Cell. 28:653-662. 
Collier,  1. E., S. M. Wilhelm, A. Z. Eisen, B. L. Mariner, G. A. Grant, J.  L. 
Seltzer,  A.  Kronberger,  C.  He,  E.  A.  Bauer,  and G.  I. Goldberg.  1988. 
H-ras  oncogene-transformed  human bronchial epithelial cells (TBE-I) se- 
crete a single metalloproteinase capable of degrading basement membrane 
collagen.  J.  Biol. Chem. 263:6579-6587. 
Dan~, K., P. A. Andreasen, J. GrOndahl-Hansen, B. Kristensen, L. S. Nielsen, 
and L. Skriver.  1985. Plasminogen activators, tissue degradation and cancer. 
Adv.  Cancer Res. 44:146-239. 
Edwards, B. R., G. Murphy, J. J. Reynolds, R. E. Whitham, A. J. P. Docherty, 
P, Angel, and J. K. Heath. 1987. Transforming growth factor beta modulates 
the expression of collagenase and metalloproteinase inhibitor, EMBO (Eur. 
Mol.  Biol. Organ.)J.  6:1899-1904. 
Folkman, J. 1986. How is blood vessel growth regulated in normal and neoplas- 
tic  tissue?  G.  H.  A.  Clowes  Memorial  Award  Lecture.  Cancer Res. 
46:467-473. 
Folkman, J., C. Haudenschild, and B. Zetter.  1979. Longterm culture of capil- 
lary endothelial cells.  Proc. Natl. Acad.  Sci. USA. 76:5217-5221. 
Furie, M. B., E. B. Cramer,  B. L. Naprstek, and S. C. Silverstein.  1984. Cul- 
tured capillary endothelial cell monolayers that restrict the transendothelial 
passage of macromolecules  and electrical  current.  J.  Cell Biol. 98:1022- 
1041. 
Gavrilovic, J., J. J. Reynolds, and G. Murphy.  1985. Inhibition of type I colla- 
gen film degradation by tumor cells using a specific antibody to collagenase 
and the specific tissue inhibitor of metalloproteinases (TIMP). Cell Biol. Int. 
Rep.  9:1097-1107. 
Gimbrone,  M. A., Jr., R. S. Cotran,  and J.  Fokman.  1974. Human vascular 
endothelial  cells  in  culture.  Growth  and  DNA  synthesis.  J.  Cell Biol. 
60:673-680. 
Gospodarowicz,  D., G.  Neufeld,  and L.  Schweigerer.  1986. Molecular and 
biological characterization  of fibroblast growth factor, an angiogenic factor 
which also controls  the proliferation  and differentiation of mesoderm and 
neuroectoderm  derived  ceils.  Cell Differ.  19:1-17. 
Gross, J. L., D. Moscatelli,  and D. B.  Rifkin.  1983. Increased capillary en- 
dothelial cell protease  activity  in response to angiogenic  stimuli in vitro. 
Proc.  Natl. Acad.  Sci. USA. 80:2623-2627. 
Heisel,  M.,  W.  E.  Laug,  and  P.  A.  Jones.  1983. Inhibition  by bovine en- 
dothelial cells of degradation by HT- 1080 fibrosarcoma cells of extracellular 
matrix proteins.  J. Natl. Cancer Inst. 71:1183-1187. 
Heussen, C., F. Joubert, and E. B. Dowdle.  1984. Purification of human tissue 
plasminogen  activator  with  Erythrina  trypsin  inhibitor.  J.  Biol. Chem. 
259:11635-11638. 
Hoal, E. G., E. L. Wilson, and E. B. Dowdle.  1983. The regulation of tissue 
plasminogen activator  activity by human fibroblasts.  Cell. 34:273-279. 
Kalebic, T., S. Garbisa,  B. Glaser,  and L.  A. Liotta.  1983. Basement mem- 
brane collagen: degradation by migrating endothelial cells. Science (Wash. 
DC). 221:281-283. 
Knudsen, B. S., R. L. Silverstein,  L. L. K. Leung,  P.  C. Harpel,  and R. L. 
Nachman.  1986. Binding of plasminogen to extracellular  matrix. J.  Biol. 
Chem. 261:10765-10771. 
Knudsen, B. S., P. C. Harpei, and R. L. Nachman.  1987. Plasminogen activa- 
tor is associated with the extracellular matrix of  cultured bovine smooth mus- 
cle cells. J.  Clin. Invest. 80:1082-1089. 
Kramer,  R. H., K. G.  Vogel,  and G.  L.  Nicolson.  1982. Solubilization and 
degradation  of subendothelial  matrix  glycoproteins  and proteoglycans  by 
metastatic tumor cells. J.  Biol. Chem. 257:2678-2686. 
Kristensen, P., L. I. Larsson,  L. S. Nielsen, J. GrOondal-Hansen, P. A. An- 
dreasen,  and K. Dane.  1984. Human endothelial cells contain one type of 
plasminogen activator.  FEBS (Fed. Eur. Biochem.  Soc.) Lett. 168:33-37. 
Lahio, M., O. Saksela, and J. Keski-Oja.  1986a. Transforming  growth factor 
B alters plasminogen activator activity in human skin fibroblasts. Exp. Cell 
Res.  164:399-407. 
Laiho, M.,  .O. Saksela, P. A. Andreasen, and J. Keski-Oja.  1986b. Enhanced 
production and cellular deposition of the endothelial-type plasminogen acti- 
vator inhibitor in cultured human lung fibroblasts by transforming  growth 
factor-B. J.  Cell Biol. 103:2403-2410. 
Laug, W. E., M. E. Weinblatt, and P. A. Jones. Endothelial cells degrade ex- 
tracellular  matrix proteins produced in vitro.  Thromb. Haemostasis. 54(2): 
49g-502. 
Levin, E. G., and D. J. Loskutoff. 1982. Cultured bovine endothelial cells pro- 
duce  both urokinase  and  tissue-type  plasminogen  activator.  Z  Cell Biol. 
94:631-636. 
Levin, E. G., and L. Santell. 1987. Association ofplasminogen activator inhibi- 
tor (PAl-1) with the growth substratum and membrane of human endothelial 
cells. J.  Cell BioL 105:2543-2549. 
Liotta, L. A., C. W. Lee, and D. J. Morakis.  1980. New method for preparing 
large  surfaces  of intact human  basement  membrane  for tumor invasion 
studies.  Cancer Lett.  11:141-152. 
Liotta, L. A., C. N. Rao, and S. H. Barsky.  1983. Tumor invasion and the ex- 
tracellular  matrix. Lab. Invest. 49:636-649. 
Lobb,  R., J.  Sasse,  R.  Sullivan,  Y. Shing,  P.  D'Amore.  J.  Jacobs,  and M. 
Klagsburn.  1986. Purification and characterization  of heparin-binding  en- 
dothelial cell growth factors. J.  Biol. Chem. 261:1924-1928. 
Lurid, L. R., A. Riccio, P.  A. Andreasen,  L.  S.  Nielsen, P.  Kristensen,  M. 
Laiho,  O.  Saksela,  F.  Blasi, and  K.  Dane.  1987. Transforming  growth 
factor-3 is a strong and fast acting positive regulator of the level of typed 
plasminogen activator  inhibitor  mRNA  in WI-38 human lung fibroblasts. 
EMBO  (Eur. Mol. Biol. Organ.)J.  6:1281-1286. 
Madri, J. A., S. K. Williams, T. Wyatt, and C. Mezzio.  1983. Capillary en- 
dothelial cell cultures: phenotypic modulation by matrix components. J. Cell 
Biol. 97:153-165. 
Mainardi,  C. L., S. N. Dixit, and A. H. Kang.  1980. Degradation of type IV 
(basement membrane) collagen by a proteinase  isolated from human poly- 
morphonuclear  leukocytes. J.  BioL Chem. 255:5435-5441. 
Mignatti, P., E. Robbins, and D. B. Rifkin.  1986. Tumor invasion through the 
human  amniotic  membrane:  requirement  for a  proteinase  cascade.  Cell. 
47:487-498. 
Miles, L. A., and E. F. Plow.  1985. Binding and activation of plasminogen on 
the platelet surface. J.  Biol. Chem. 260:4303-4311. 
Mimuro, J., R. R. Schleef, and D. J. Loskutoff.  1987. Extracellular matrix of 
cultured bovine aortic endothelial cells contains functionally active type  1 
plasminogen activator inhibitor.  Blood.  70:721-728. 
Montesano, R., and L. Orci.  1985. Tumor-producing phorbol esters induce an- 
giogenesis in vitro. Cell. 42:469-477. 
Montesano, R., and L. Orci.  1987. Phorbol esters induce angiogenesis in vitro 
from large vessel endothelial cells. J.  Celt. Physiol.  130:284-291. 
Montesano, R., L. Orci, and J. D. Vassalli.  1983. In vitro rapid organization 
of endothelial cells into capillary-like networks is promoted by collagen ma- 
trices. J.  Cell Biol. 97:1648-1652. 
Montesano, R., M. S. Pepper, J. D. Vassalli, and L. Orci.  1987. Phorbol ester 
induces cultured endothelial cells to invade a fbrin matrix in the presence 
of fibrinolytic inhibitors. J.  Cell. PhysioL 132:509-516. 
Montesano, R., J. D. Vassalli, A. Baird, R. Guillemin, and L. Orci.  1986. Ba- 
sic fibroblast growth factor induces angiogenesis in vitro. Proc. Natl. Acad. 
Sci.  USA. 83:7297-7301. 
Moscatelli,  D.  1986. Urokinase-type and tissue-type plasminogen activators 
have different distributions  in cultured bovine capillary endothelial cells. J. 
Cell. Biochem.  30:19-29. 
Moscatelli, D., and D. B. Rifkin.  1988. Membrane and matrix localization of 
proteases:  a common theme in tumor invasion and angiogenesis. Biochim. 
Biophys. Acta.  948:67-85. 
Moscatelli, D., M. Presta, and D. B. Rifkin.  1986. Purification of a factor from 
human placenta that stimulates capillary endothelial cell protease production, 
DNA synthesis, and migration. Proc. Natl. Acad. Sci. USA. 83:2091-2095. 
Muller, G., J. Behrens, U. Nussbaumer, P. B6hlen, and W. Birchmeier.  1987. 
Mignatti et al. Role of bFGF and Proteinases in In  Vitro Angiogenesis  681 Inhibitory action of transforming growth factor B on endothelial cells. Proc. 
Natl.  Acad.  Sci.  USA.  84:5600-5604. 
Mullins, D. E., and S. T. Rohrlich.  1983. The role of proteinases in cellular 
invasiveness. Biochim.  Biophys.  Acta.  695:177-214. 
Murphy, J., M. 1. Cockett, T. E. Stephens, D. J. Smith, and A. J.  Docherty. 
1987.  Stromelysin  is  an  activator  of procollagenase.  Biochem.  J.  248: 
265-268. 
Nicosia, R. F., R. Tchao, and J. Leighton.  1983. Angiogenesis-dependent tu- 
mor spread in reinforced fibrin clot culture.  Cancer Bes. 43:2159-2166. 
O'Grady, R. L., L. I. Upfold, and R. W. Stephens. 1981. Rat mammary carci- 
noma cells secrete active collagenase and activate latent enzyme in the stroma 
via plasminogen activator.  Int.  J.  Cancer.  28:509-515. 
Paranjpe, M., L. Engel, N. Young, and L. A. Liotta.  1980. Activation of hu- 
man breast carcinoma collagenase through plasminogen activator. Life Sci. 
26:1223-1231. 
Pepper,  M. S., J. D. Vassalli, R. Montesano, and L. Orci.  1987. Urokinase- 
type  plasminogen  activator  is  induced in  migrating  capillary  endothelial 
cells. J.  Cell Biol.  105:2535-2541. 
Persky, B., L. E. Ostrowsky, P. Pogast, A. Ahsan, and R. M. Schultz.  1986. 
Inhibition of proteolytic enzymes in the in vitro amnion model for basement 
membrane invasion.  Cancer Res.  46:4129-4134. 
Pipoly, D. J., and E. C. Crouch.  1987. Degradation of native type IV procolla- 
gen  by  human  neutrophil  elastase.  Implications  for  leukocyte-mediated 
degradation of basement membranes. Biochemistry.  26:5748-5754. 
Plow, E. F., D. E. Freaney, J. Plescia, and L. A. Miles.  1986. The plasmino- 
gen system and cell surfaces: evidence for plasminogen and urokinase recep- 
tors on the same cell type. J.  Cell Biol.  103:2411-2420. 
Pfll~inen, J., O. Saksela, E. M. Salonen, P. Andreasen, L. Nielsen, K. Dane, 
and A. Vaheri. 1987. Distinct localization of urokinase type plasminogen ac- 
tivator and its type 1 inhibitor under cultured human fibroblasts and sarcoma 
cells. J.  Cell Biol.  104:1085-1096. 
P611iinen, J., K. Hedman, L. S. Nielsen, K. Dan0, and A. Vaheri.  1988. Ultra- 
structural localization of plasma membrane-associated urokinase-type plas- 
minogen activator at focal contacts. J.  Cell Biol.  106:87-95. 
Presta,  M.,  D.  Moscatelli,  J.  Joseph-Silverstein,  and  D.  B.  Rifkin. 1986. 
Purification from a human hepatoma cell line of a basic fibroblast growth 
factor-like molecule that stimulates capillary endothelial cell plasminogen 
activator  production,  DNA  synthesis,  and  migration.  Mol.  Cell.  Biol. 
6:4060-4066. 
Quigley, J. 1976. Association ofa protease (PA) with a specific membrane frac- 
tion isolated from transformed cells. J.  Cell Biol.  71:472-486. 
Saksela, O., D. Moscatelli, and D. B. Rifkin.  1987. The opposing effects of 
basic fibroblasts growth factor and transforming growth factor beta on the 
regulation of plasminogen activator activity in capillary endothelial cells. J. 
Cell Biol.  105:957-963. 
Salo, T., L. A. Liotta, J. Keski-Oja, T. Turpeenniemi-Hujanen, and K. Trygg- 
vason.  1982. Secretion of basement membrane collagen degrading enzyme 
and plasminogen activator by transformed cells-role in metastasis. Int.  J. 
Cancer.  30:669-673. 
Sato, Y., and D. B. Rifkin. 1988. Autocrine activities of basic fibroblast growth 
factor: regulation of endothelial cell movement, plasminogen activator syn- 
thesis, and DNA synthesis. J.  Cell Biol.  107:1199-1205. 
Schweigerer,  L., G. Neufeld, J. Friedman, J. A. Abraham, J. C. Fiddes, and 
D. Gospodarowicz.  1987. Capillary endothelial cells express basic fibroblast 
growth factor, a mitogen that promotes their own growth. Nature  (Lond.). 
325:257-259. 
Sporn,  M.  B.,  A. B.  Roberts,  L.  M.  Wakefield, and R.  K.  Assoian.  1986. 
Transforming growth factor B: biological functions and chemical structure. 
Science  (Wash.  DC).  233:532-534. 
Stoppelli, M. P., C. Tacchetti, M.  V. Cubellis, A. Corti,  V. J. Hearing,  G. 
Cassani,  E.  Appella,  and  F.  Blasi. 1986. Autocrine  saturation  of pro- 
urokiuase receptors on human A431 cells.  Cell.  45:675-684. 
Van Hinsbergh, V. W. M., E. D. Sprengers, and T. Kooistra.  1987. Effect of 
thrombin on the production of plasminogen activator and PA Inhibitor-1 by 
human  foreskin  microvascular  endothelial  cells.  Throrab.  Haemostasis. 
57:148-153. 
Vassalli, J. D., D. Baccino, and D. Belin. 1985. A cellular binding site for the 
Mr 55,000  form of the  human plasminogen  activator,  urokinase.  J.  Cell 
Biol.  100:86-92. 
Werb, Z., C. Mainardi, C. A. Vater, and E. D. Harris.  1977. Endogenous acti- 
vation of latent collagenase by rheumatoid synovial cells. Evidence for a role 
of plasminogen activator.  New Engl.  J.  Med.  296:1017-1023. 
Werb, Z., M. J. Banda, and P. A. Jones.  1980. Degradation of connective tis- 
sue matrices by macrophages.  I. Proteolysis of elastin,  glycoproteins and 
collagen  by  proteinases  isolated  form macrophages.  J.  Exp.  Med.  152: 
1340-1357. 
Wilhelm,  S.  M., I. E. Collier,  A. Kronberger,  A. Z.  Eisen, B. L.  Marmer, 
G. A. Grant,  E. A. Bauer, and G. Goldberg.  1987. Human skin fibroblast 
stromelysin:  structure,  glycosilation,  substrate specificity, and differential 
expression  in normal and tumorigenic cells.  Proc.  Natl.  Acad.  Sci.  USA. 
84:6725-6729. 
Yurchenco,  P. D., and G. C. Ruben.  1987. Basement membrane structure in 
situ: evidence for lateral associations in the type IV collagen network. J. Cell 
Biol.  105:2559-2568. 
The Journal of Cell Biology, Volume  108, 1989  682 